“As we enter the new era of precision medicine, it is essential to disseminate as efficiently as possible the advances that catalyze the translation of scientific breakthroughs into patient care. I am very excited to join Frontiers in Medicine to make this journal a key part of this endeavor” – Prof Goldman
Michel Goldman, MD, PhD is Professor of Immunology and Pharmacotherapy at the Université Libre de Bruxelles. In his career as clinician scientist, he was always particularly passionate about the translational aspects of medical research. This led him to become in 2009 the first Executive Director of the Innovative Medicines Initiative (IMI), a partnership between the European Commission and the European Federation of Pharmaceutical Industries aiming at building networks of industrial and academic experts to boost pharmaceutical innovation in Europe. Prof Goldman is now leading the Institute for Interdisciplinary Innovation in Healthcare (I3h) in Brussels, whose mission is to foster research, education and outreach networks for the benefit of patients and other healthcare stakeholders.
“I accepted with enthusiasm the invitation to become the Field Chief Editor of Frontiers in Medicine as the key principles of transparency and collaboration that characterize the Frontiers journals are also at the core of the I3h Institute” – Prof Goldman
As outlined in the mission statement, Frontiers in Medicine will give particular attention to papers focused on cutting-edge therapies including stem cells, gene therapies and regenerative medicine products, as well as to interdisciplinary studies that are directly relevant to patient care.
If you are interested in joining the Editorial Board of Frontiers in Medicine, or if you have any questions for Prof Goldman, please contact email@example.com for more information. We look forward to hearing from you!